ストックスクリーナーアプリを入手
114.97
4.37%
-5.26
アフターアワーズ：
114.60
-0.37
-0.32%
Glaukos Corp (GKOS) 最新ニュース
Glaukos (GKOS) Faces Selling Pressure Amid iDose Procedure Conce - GuruFocus
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Midday Stock Roundup: Glaukos Corp. Shares Drop 11% - Orange County Business Journal
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest - AD HOC NEWS
Glaukos director Kliman sells $703,800 in stock - Investing.com
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at $146.90 - Investing.com UK
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp stock (US3773221029): eye-care specialist gains attention after FDA approval and strong - AD HOC NEWS
Glaukos (GKOS) price target increased by 12.59% to 154.96 - MSN
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding - Stock Titan
Glaukos (GKOS) Stock Price, News & Analysis - MarketBeat
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares - Stock Titan
Glaukos stock (US3773221029): Director sale signals confidence near 52-week highs - AD HOC NEWS
Glaukos director Gilbert H Kliman sells $675,000 of company stock - Investing.com UK
Glaukos director Gilbert H Kliman sells $675,000 of company stock By Investing.com - Investing.com South Africa
TradingKey - TradingKey
Glaukos Corp stock (US3773221029): Insider files Form 144 for 5,000-share sale - AD HOC NEWS
Glaukos Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
How to watch Glaukos at four upcoming investor conferences - Stock Titan
[144] GLAUKOS Corp SEC Filing - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Number of shareholders of Glaukos Corp – LS:A14VCK - TradingView
Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile - AD HOC NEWS
Glaukos Corp. Hits New 52-Week High at $145.50, Reflecting Strong Growth - Markets Mojo
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares - Investing.com Australia
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares By Investing.com - Investing.com South Africa
Glaukos president & COO Gilliam sells $2.8m in company stock - Investing.com Australia
Glaukos president & COO Gilliam sells $2.8m in company stock By Investing.com - Investing.com South Africa
Glaukos (GKOS) CFO exercises options and sells 10,000 shares under plan - Stock Titan
GLAUKOS (GKOS) President & COO sells 19,573 shares in open-market trade - Stock Titan
GLAUKOS (GKOS) director Leana Wen sells 1,700 shares, holds 19,739 - Stock Titan
Glaukos Corp Leads Innovation in Chronic Eye Disease Treatment with iDose TR and Epioxa Therapies – 2026 Investor Update - Minichart
Glaukos to present May 2026 investor slide deck highlighting iDose TR, Epioxa launch and 2026 guidance - TradingView
[8-K] GLAUKOS Corp Reports Material Event - Stock Titan
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations - Yahoo Finance
UBS Group AG Increases Position in Glaukos Corporation $GKOS - MarketBeat
1.27%
2.05%
大文字化:
|
ボリューム (24 時間):